SRTA
Strata Critical Medical, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-29/100
Last price
4.75
▼ 0.06 (1.25%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
4.71
Prev close
4.81
Day high
4.85
Day low
4.72
Volume
760.50K
Market cap
$420.22M
P/E (TTM)
—
52W range
3.95 – 6.50
Day trading desk
Gap from prior close
-2.08%
Prior close 4.81
VWAP
4.76
-0.26% from price
Relative volume
0.71×
Normal
Session range
2.97%
4.71 – 4.85
Position in range
29%
Near session low
ATR (14D)
0.21
4.34% of price
Prior day high
4.91
PDH
Prior day low
4.68
PDL
Bid / ask spread
—
Quote not published
Session volume
671.52K
Avg 940.57K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-6.86%
-8.8%
1M
-10.71%
-11.9%
3M
-7.95%
-12.5%
6M
+17.00%
-1.2%
YTD
-1.25%
-15.5%
1Y
-12.20%
-28.6%
3Y
+83.40%
+1.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SRTA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+2.28M
Net buying
Buy transactions
13
2.42M shares
Sell transactions
7
141.88K shares
Net transactions
+20
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
12.67M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 10, 26 | LOVE REGINALD LAMONTE Director |
SELL | 5.09K | $29.27K | Direct |
| Jul 30, 26 | WIESENTHAL ROBERT S Director |
STOCK | 50.23K | $0 | Direct |
| Jul 30, 26 | LOVE REGINALD LAMONTE Director |
STOCK | 37.67K | $0 | Direct |
| Jul 30, 26 | PHILIP EDWARD M Director |
STOCK | 30.91K | $0 | Direct |
| Jul 30, 26 | HEYBURN WILLIAM A Chief Executive Officer |
STOCK | 360.23K | $0 | Direct |
| Jul 30, 26 | TOMKIEL MELISSA M. Chief Executive Officer |
STOCK | 415.88K | $0 | Direct |
| Jul 30, 26 | COHEN AMIR Officer |
STOCK | 69.21K | $0 | Direct |
| Jul 30, 26 | LAUCK ANDREW Director |
STOCK | 35.26K | $0 | Direct |
| Jul 30, 26 | WUNSCH SCOTT M Officer |
STOCK | 57.17K | $0 | Direct |
| Jul 30, 26 | COOK WILLIAM L III Director |
STOCK | 44.44K | $0 | Direct |
| Jun 8, 26 | HEYBURN WILLIAM A Chief Executive Officer |
SELL | 31.67K | $185.91K | Direct |
| Jun 8, 26 | TOMKIEL MELISSA M. Chief Executive Officer |
SELL | 29.73K | $174.51K | Direct |
| Jun 8, 26 | COHEN AMIR Officer |
SELL | 4.66K | $27.32K | Direct |
| Jun 8, 26 | WUNSCH SCOTT M Officer |
SELL | 5.55K | $32.58K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AFFELDT ERIC L |
Director | 581.21K | Stock Award(Grant) |
BORTHWICK JOHN |
Director | 203.98K | Stock Award(Grant) |
HEYBURN WILLIAM A |
Chief Executive Officer | 1.71M | Stock Award(Grant) |
LERER KENNETH B |
Director | 254.59K | Stock Award(Grant) |
LYNE SUSAN M |
Director | 187.19K | Stock Award(Grant) |
PHILIP EDWARD M |
Director | 265.08K | Stock Award(Grant) |
TOMKIEL MELISSA M. |
Chief Executive Officer | 2.10M | Stock Award(Grant) |
VERDETTO LOUIS R |
Officer | 1.27M | Stock Award(Grant) |
WIESENTHAL ROBERT S |
Director | 5.33M | Stock Award(Grant) |
WUNSCH SCOTT M |
Officer | 1.05M | Stock Award(Grant) |
Fundamentals
Market cap$420.22M
Enterprise value$401.72M
Revenue (TTM)$255.98M
Gross profit$54.40M
EBITDA$7.22M
Net income$-23.16M
EPS (TTM)$-0.28
Free cash flow$-20.09M
Total cash$22.75M
Total debt$4.25M
Book value / share$3.16
Shares outstanding88.47M
Float58.11M
Short % of float6.25%
Dividend yield0.00%
Beta (5Y)2.43
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book1.50
EV / revenue1.57
EV / EBITDA55.62
Gross margin21.25%
Operating margin-6.32%
Profit margin15.71%
Return on equity-9.22%
Return on assets-1.86%
Debt / equity1.52
Current ratio2.64
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $197.14M | $146.82M | $225.18M | $146.12M | +34.3% |
| Operating revenue | $197.14M | $146.82M | $225.18M | $146.12M | +34.3% |
| Cost of revenue | $156.01M | $117.23M | $183.06M | $123.84M | +33.1% |
| Gross profit | $41.13M | $29.59M | $42.12M | $22.27M | +39.0% |
| Research & development | — | $3.18M | $4.63M | $5.54M | — |
| Selling, general & admin | $60.88M | $50.86M | $105.61M | $70.26M | +19.7% |
| Total operating expense | $63.48M | $52.11M | $110.24M | $75.80M | +21.8% |
| Operating income | -$22.35M | -$22.52M | -$68.12M | -$53.53M | +0.8% |
| Net interest income | $4.24M | $7.21M | $8.44M | $3.43M | -41.2% |
| Pre-tax income | -$20.07M | -$16.16M | -$57.54M | -$28.03M | -24.2% |
| Tax provision | $0 | $0 | -$1.47M | -$772.00K | — |
| Net income | $41.35M | -$27.31M | -$56.08M | -$27.26M | +251.4% |
| Net income to common | $41.35M | -$27.31M | -$56.08M | -$27.26M | +251.4% |
| Basic EPS | 0.48 | -0.34 | -0.76 | -0.38 | +238.7% |
| Diluted EPS | 0.48 | -0.34 | -0.76 | -0.38 | +238.7% |
| EBIT | -$22.35M | -$22.52M | -$68.12M | -$53.53M | +0.8% |
| EBITDA | -$14.17M | -$16.56M | -$61.01M | -$47.80M | +14.5% |
| Basic shares | 86.70M | 79.42M | 73.52M | 71.66M | +9.2% |
| Diluted shares | 86.70M | 79.42M | 73.52M | 71.66M | +9.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $30.97M | $16.07M | $27.87M | $41.34M | +92.7% |
| Cash & short-term investments | $61.23M | $124.83M | $166.14M | $192.08M | -50.9% |
| Accounts receivable | $39.96M | $19.82M | $21.00M | $10.88M | +101.6% |
| Total current assets | $126.19M | $160.74M | $206.26M | $218.13M | -21.5% |
| Property, plant & equipment | $39.55M | $31.30M | $26.38M | $19.73M | +26.4% |
| Goodwill & intangibles | $135.71M | $23.50M | $60.89M | $85.81M | +477.4% |
| Total assets | $325.47M | $256.68M | $294.94M | $325.02M | +26.8% |
| Total current liabilities | $19.79M | $22.73M | $35.49M | $26.61M | -12.9% |
| Total debt | $3.31M | $3.02M | $24.52M | $18.33M | +9.6% |
| Total liabilities | $46.40M | $34.74M | $60.64M | $50.54M | +33.6% |
| Retained earnings | -$145.55M | -$186.90M | -$159.75M | -$103.68M | +22.1% |
| Shareholder equity | $279.07M | $221.94M | $234.30M | $274.49M | +25.7% |
| Working capital | $106.40M | $138.02M | $170.77M | $191.52M | -22.9% |
| Net tangible assets | $143.36M | $198.43M | $173.41M | $188.68M | -27.8% |
| Shares issued | 86.70M | 79.42M | 75.13M | 71.66M | +9.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $41.35M | -$27.31M | -$56.08M | -$27.26M | +251.4% |
| Depreciation & amortisation | $8.19M | $5.96M | $7.11M | $5.72M | +37.3% |
| Stock-based compensation | $17.83M | $19.89M | $12.50M | $8.28M | -10.4% |
| Change in working capital | -$9.08M | -$3.01M | -$6.74M | -$17.00K | -201.8% |
| Operating cash flow | -$48.91M | -$2.52M | -$32.35M | -$37.13M | -1,841.8% |
| Capital expenditure | -$11.01M | -$32.98M | -$2.11M | -$730.00K | +66.6% |
| Investing cash flow | $69.75M | -$1.02M | $17.09M | $79.34M | +6,965.2% |
| Share buybacks | $0 | -$244.00K | $0 | — | +100.0% |
| Financing cash flow | -$8.91M | -$5.76M | -$76.00K | -$1.08M | -54.7% |
| Free cash flow | -$59.92M | -$35.50M | -$34.46M | -$37.86M | -68.8% |
| End cash position | $31.23M | $19.65M | $29.02M | $44.42M | +59.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $72.51M | $67.38M | $66.79M | $49.30M | $45.11M | — | +7.6% |
| Operating revenue | $72.51M | $67.38M | $66.79M | $49.30M | $45.11M | — | +7.6% |
| Cost of revenue | $57.29M | $53.27M | $55.12M | $37.68M | $36.10M | — | +7.6% |
| Gross profit | $15.21M | $14.12M | $11.67M | $11.61M | $9.01M | — | +7.8% |
| Research & development | $1.01M | — | — | $453.00K | $696.00K | $812.00K | — |
| Selling, general & admin | $12.89M | $15.61M | $16.82M | $16.78M | $12.58M | — | -17.4% |
| Total operating expense | $20.62M | $17.09M | $18.07M | $17.24M | $13.65M | — | +20.7% |
| Operating income | -$5.41M | -$2.97M | -$6.41M | -$5.62M | -$4.64M | — | -81.8% |
| Net interest income | $331.00K | $473.00K | $638.00K | $1.13M | $1.16M | — | -30.0% |
| Pre-tax income | -$10.52M | $2.40M | -$5.39M | -$9.66M | -$3.41M | — | -537.8% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$10.52M | $2.15M | -$8.83M | $57.42M | -$3.74M | — | -588.2% |
| Net income to common | -$10.52M | $2.15M | -$8.83M | $57.42M | -$3.74M | — | -588.2% |
| Basic EPS | -0.12 | 0.03 | -0.10 | 0.70 | -0.05 | — | -500.0% |
| Diluted EPS | -0.12 | 0.03 | -0.10 | 0.70 | -0.05 | — | -500.0% |
| EBIT | -$5.41M | -$2.97M | -$6.41M | -$5.62M | -$4.64M | — | -81.8% |
| EBITDA | $3.11M | $86.00K | -$3.40M | -$3.92M | -$2.87M | — | +3,512.8% |
| Basic shares | 86.21M | 85.32M | 86.70M | 82.45M | 81.30M | — | +1.0% |
| Diluted shares | 86.21M | 90.17M | 86.70M | 82.45M | 81.30M | — | -4.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $16.32M | $58.72M | $30.97M | $22.75M | $58.75M | -72.2% |
| Cash & short-term investments | $22.75M | $58.79M | $61.23M | $75.92M | $113.42M | -61.3% |
| Accounts receivable | $43.41M | $39.60M | $39.96M | $37.54M | $28.17M | +9.6% |
| Total current assets | $121.01M | $124.14M | $126.19M | $122.48M | $156.48M | -2.5% |
| Property, plant & equipment | $44.64M | $44.28M | $39.55M | $41.84M | $42.15M | +0.8% |
| Goodwill & intangibles | $166.95M | $134.90M | $135.71M | $134.36M | $57.83M | +23.8% |
| Total assets | $332.70M | $327.62M | $325.47M | $335.08M | $257.92M | +1.6% |
| Total current liabilities | $45.78M | $20.94M | $19.79M | $27.87M | $26.31M | +118.6% |
| Total debt | $4.25M | $4.47M | $3.31M | $3.47M | $8.84M | -4.8% |
| Total liabilities | $53.38M | $41.89M | $46.40M | $52.08M | $34.82M | +27.4% |
| Retained earnings | -$153.91M | -$143.40M | -$145.55M | -$136.72M | -$194.13M | -7.3% |
| Shareholder equity | $279.32M | $285.73M | $279.07M | $283.00M | $223.10M | -2.2% |
| Working capital | $75.23M | $103.20M | $106.40M | $94.61M | $130.17M | -27.1% |
| Net tangible assets | $112.36M | $150.83M | $143.36M | $148.64M | $165.27M | -25.5% |
| Shares issued | 88.47M | 86.52M | 86.70M | 86.05M | 81.70M | +2.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$10.52M | $2.15M | -$8.83M | $57.42M | -$3.74M | -588.2% |
| Depreciation & amortisation | $8.52M | $3.06M | $3.01M | $1.70M | $1.78M | +178.3% |
| Stock-based compensation | $3.71M | $5.04M | $6.59M | $1.68M | $5.35M | -26.4% |
| Change in working capital | -$1.72M | -$1.46M | -$11.86M | $7.99M | -$6.03M | -17.3% |
| Operating cash flow | $5.69M | $3.88M | -$8.31M | -$37.30M | -$3.06M | +46.4% |
| Capital expenditure | -$2.80M | -$5.48M | -$2.00M | -$3.19M | -$2.66M | +48.8% |
| Investing cash flow | -$43.88M | $24.73M | $18.27M | $2.40M | $28.68M | -277.4% |
| Share buybacks | — | — | $0 | $0 | — | — |
| Financing cash flow | -$4.21M | -$859.00K | -$1.74M | -$1.79M | -$1.14M | -390.3% |
| Free cash flow | $2.88M | -$1.60M | -$10.31M | -$40.49M | -$5.73M | +280.6% |
| End cash position | $16.58M | $58.99M | $31.23M | $23.02M | $60.32M | -71.9% |
Options analytics
Put / call volume
1.09
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
5.00
+5.3% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
-12.5%
Calls bid over puts
Call volume
11
Contracts, this expiry
Put volume
12
Contracts, this expiry
Heaviest call OI
5.00
0 contracts
Heaviest put OI
5.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.02 | -0.12 | -500.0% |
| Mar 2026 | -0.04 | 0.04 | +212.0% |
| Dec 2025 | -0.01 | -0.06 | -500.0% |
| Sep 2025 | -0.02 | -0.12 | -500.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.01 | 4 | $72.67M | +47.4% |
| Next quarter | 0.01 | 4 | $78.26M | +17.2% |
| Current year | -0.09 | 4 | $290.80M | +47.5% |
| Next year | 0.00 | 3 | $326.10M | +12.1% |
Analyst targets & ownership
Mean target$9.56
High target$12.75
Low target$8.00
Implied upside101.32%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders14.32%
Held by institutions71.59%
Institutions holding183
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
5.05
-6.02% from price
SMA 20
5.18
-8.26% from price
SMA 50
5.49
-13.44% from price
SMA 100
5.52
-13.89% from price
SMA 200
5.16
-7.99% from price
EMA 12
5.03
-5.62% from price
EMA 26
5.22
-9.04% from price
EMA 50
5.34
-11.09% from price
RSI (14)
32.4
Neutral
MACD (12,26,9)
-0.19
Hist -0.05
ATR (14)
0.21
4.34% of price
Realised vol 30D
36.6%
Annualised
Bollinger upper
5.62
20, 2σ
Bollinger lower
4.73
20, 2σ
50 / 200 cross
Golden
5.49 vs 5.16
Trend bias
Below 200
-7.99%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.03
More volatile than market
Correlation to SPY
0.47
Loosely linked
Realised vol 30D
36.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-32.2%
Peak to trough
Max drawdown 5Y
-81.3%
Peak to trough
ATR 14
0.21
4.34% of price
Beta (reported)
2.43
5Y monthly, from filing
Short interest
Shares short
4.36M
Prior 4.19M
Change vs prior
+3.9%
Shorts adding
% of float
6.25%
Normal
% of shares out
4.93%
Against total outstanding
Days to cover
5.2
Crowded exit
Float
58.11M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 25, 26 | Craig-Hallum | INITIATED | — | Buy |
| Mar 25, 26 | B. Riley Securities | INITIATED | — | Buy |
| Sep 17, 25 | Lake Street | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-03
Corporate Changes & Voting Matters
8-K · 2026-05-06
Proxy Statements
DEFA14A · 2026-04-14
Corporate Changes & Voting Matters
8-K · 2026-03-03
Corporate Changes & Voting Matters
8-K · 2026-02-05
Corporate Changes & Voting Matters
8-K · 2025-12-03
Corporate Changes & Voting Matters
8-K/A · 2025-12-02
Headlines
Strata Critical to Present at the 2026 Jefferies Healthcare Services and Technology Conference
GlobeNewswire · 28d ago
NACD Announces Finalists for 2026 Directorship 100 B. Kenneth West Lifetime Achievement Award and Directors of the Year
PR Newswire · 44d ago
Strata Critical Medical, Inc. (SRTA) Upgraded to Buy: What Does It Mean for the Stock?
Zacks · 44d ago
Does Strata Critical Medical, Inc. (SRTA) Have the Potential to Rally 47.28% as Wall Street Analysts Expect?
Zacks · 44d ago
Strata Critical Medical (SRTA) Q2 2026 Earnings Call Transcript
Motley Fool · 57d ago
Immersion Investment Views Strata Critical Medical (SRTA) as a “Babushka Doll”
Insider Monkey · 57d ago
Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?
Zacks · 62d ago
Strata Critical Medical, Inc. Q2 2026 Earnings Call Summary
Moby · 63d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.